Osteoclasts and hematopoiesis
and Slavin 11 hypothesized that there is a hematological etiology of osteoporosis. They suggested that, because blood loss creates developmental pressure on the hematopoietic system, the number of hematopoietic cells increases. These include the monocyte-derived osteoclasts, which intensify resorption and sustain the extension of the space available for hemato poiesis. In support of their proposal, patients affected by hematological diseases accompanied by chronic anemia or hemophilia, or treated with anticoagulants, tend to develop osteoporosis. 12 -14 To demonstrate this theory, they used a preclinical model of ectopic transplantation of a bone marrow plug into the subcapsular space of the mouse kidney, which triggers mesenchymal progenitor cells from the transplant into the development of bone and hematopoietic microenvironment. 15 Mice were then subjected to blood-letting for 10 months (about 1 / 3 of their lifespan). The overall features of the ectopic ossicles developed in the chronically bled mice confirmed the assumption of the authors as they showed more hematopoiesis and less bone development compared with the ossicles formed in mice not subjected to blood withdrawal. 11 However, the results using other experimental models were not in line with this hypothesis. In fact, in ovariectomized rats, Lei et al. 16 observed that there is a time-dependent bone loss associated with an increase in osteoclast numbers and a parallel reduction in the volume of hematopoietic tissue. Therefore, at least in rats, these observations contradict the notion that osteoporosis is associated with an increase of hematopoiesis. 11 Osteopetrosis. Intriguingly enough, in osteopetrosis, a condition of high bone mass and hematological failure in which osteoclasts are dysfunctional, bone marrow hematopoiesis is impaired regardless of the number of osteoclasts present in the microenvironment. 17 In both osteoclast-rich and osteoclast-poor osteopetroses, which differ for the presence of a high number of non-functional osteoclasts in the former and the total absence of osteoclasts in the latter, anemia, pancytopenia and altered blood clothing are similarly observed. 17 These events are associated with an insufficient space for hematopoietic tissue to evolve. However, recent observations showed different histological aspects in osteoclast-rich and osteoclast-poor Osteoclasts and hematopoiesis A Teti osteopetrosis. 18, 19 In fact, pathological examination of the bone biopsies of osteoclast-rich osteopetrotic patients refer to ' irregular and massive primary trabeculae surrounded by abnormal fibrous tissue ' . 20, 21 In contrast, Sobacchi et al. 22 and Guerrini et al. 23 showed a few bone biopsies of osteoclast-poor patients, describing the presence of scant hematopoietic tissue in small medullary spaces, with, however, no fibrosis ( Figure 1 ). As most hallmarks of the two forms of osteopetrosis are very similar except for the presence of high number of osteoclasts versus their absence, it is worth to hypothesize that, at least in this pathological condition, nonfunctional osteoclasts may contribute to the development of fibrosis, possibly inhibiting hematopoiesis.
Role of Osteoclast Enzymes
Osteoclasts are ectoenzyme-producing cells. 10 Cathepsin K, for example, is the major collagenolytic enzyme released in the osteoclast-resorbing lacuna from the lysosomal compartment, and Kollet et al. 24 suggested that osteoclast cathepsin K meditates the cleavage of an important chemokine, CXCL12, responsible for the anchorage of HSCs to the niche, causing the mobilization of immature hematological progenitor cells into the circulation ( Figure 2 ). However, definitive conclusions on the role of cathepsin K in cleaving CXCL12 cannot be drawn yet because of the lack of data in suitable animal models, such as the cathepsin knockout mice. Kollet et al. 24 also observed that MMP-9 contributes to the recruitment of immature progenitors to the circulation by RANKL-stimulated osteoclasts in a CXCR4-dependent manner, a condition not observed in protein tyrosine phosphatase -knockout mice, which have defective osteoclasts. This progenitor egress was prevented by calcitonin, a potent inhibitor of osteoclast bone resorption ( Table 2 ) . Finally, they observed that RANKL-stimulated osteoclasts reduced osteopontin content along the endosteum, which is considered an important component of the endosteal niche that retains the HSCs in place. Consistent with these results, Heissig et al. 25 have demonstrated that recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9-mediated release of c-kit ligand, which permits the transfer of HSCs from the quiescent to the proliferative niche, indirectly suggesting a role of osteoclasts in HSC niche maintenance ( Figure 2 ). Finally, Pelus et al. 26 showed that MMP-9 is indeed involved in HSC mobilization induced by the chemokines GRO / / CXCL2 and GRO / CXCL2 4 , an event neutralized in neutrophil-depleted mice, which also lack MMP-9, and partially blocked by the MMP-9 inhibitor MeOSuc-Ala-Ala-Pro-Cal-CMK.
However, other studies argued against MMP-9 having any effect on HSC mobilization. Robinson et al. 27 and Levesque et al. 28 reported that MMP-9 knockout mice did not show impaired HSC mobilization, and that the engraftment of MMP-9-deficient bone marrow HSCs was not harmed in sublethally irradiated wild-type recipients. Therefore, more insights are necessary to fully understand the relevance of MMP-9 in the regulation of hematopoiesis.
Treatments
Treatment with strontium ranelate, a bone anabolic agent that increases osteoblast number but inhibits osteoclasts, has been observed to cause a delay in hematopoietic recovery after bone marrow transplantation, 6 supporting a role for osteoclastic regulation of HSCs ( Table 2 ). It is also believed that prostaglandin E2 expands hematopoiesis not only by increasing HSC number but also through its complex role on the metabolism of osteoblasts and osteoclasts. 29 In fact, in mice treated with prostaglandin E2, disruption of bone microarchitecture, possibly due, at least in part, to activation of bone resorption, 30 was observed along with an increase of Lineage -Sca-1 + c-Kit + (LSK) bone marrow HSCs 29 ( Table 2 ).
Role of Calcium
It is known that the activity of osteoclasts elevates the local and systemic calcium ion concentration, and recent studies have demonstrated that the HSC engraftment at the endosteal niche is specified by the calcium-sensing receptor ( Figure 2 ). In fact, Adams et al. 31 have shown reduced cellularity and HSC content in the bone marrow of calcium sensing-receptor-deficient mice. In these mice they also observed an increased mobilization of progenitors, suggesting that calcium may have a relevant role in keeping HSC localization in the bone marrow.
Genetic Studies
Genetic studies have attempted to demonstrate the molecular mechanisms whereby osteoclasts modulate hematopoiesis. For instance, the inhibitor of differentiation gene ( Id1 ), a transcriptional Cartoon showing the hypothetical role of cathepsin K (Cat-K), matrix metalloproteinase 9 (MMP-9) and calcium (Ca 2 + ) on HSC mobilization, proliferation and engraftment at the endosteal niche.
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A Teti regulator that prevents basic helix -loop -helix transcription factors from binding the DNA, 32 has been found to link bone homeostasis and hematopoiesis ( Figure 3 ). In fact, Id1 − / − mice showed an osteoporotic phenotype, with the osteoclast-specific genes, cathepsin K, tartrate-resistant acid phosphatase, and osteoclast-associated receptor upregulated, while the same genes were repressed in osteoclasts overexpressing Id1. 33 The hematopoietic compartment of Id1 − / − mice showed an increase in myeloid differentiation and HSC proliferation, suggesting that in the absence of Id1 the HSCs are driven towards myeloid differentiation. Id1 has therefore been indicated as a factor in the dynamic cross-talk between osteoclasts and HSCs, 33 although further work is necessary to confirm this hypothesis.
A recent report has shown that the CREB (cAMP response element-binding)-binding protein (CREBBP), which regulates the hematopoiesis by a HSC-intrinsic effect, has a pivotal role also in the microenvironment-mediated regulation of hematopoiesis. 34 CREBBP is a coactivator of transcription that interacts with transcription factors and acetylates histones and other proteins. In humans, chromosomal translocations involving the CREBBP gene have been reported in leukemia 35 and myelodysplastic syndromes. 36 Defects in Crebbp − / − HSCs include impaired self-renewal and exacerbated myeloid differentiation, 37 with a tendency of Crebbp − / − mice to develop hematological malignancies with age. 38 It has been observed that Crebbp − / − mice not only poorly support HSCs, promoting excessive myelopoiesis and reducing lymphopoiesis, but also show reduced bone volume due to increased osteoclastogenesis ( Figure 3 ). Interestingly, Crebbp deficiency in the bone marrow microenvironment results in reduced levels of MMP9, a metalloproteinase abundantly expressed in osteoclasts.
Role of Bone Marrow Monocytic Cells
Monocytes share with osteoclasts the same origin from the granulocyte / macrophage colony-forming unit. Therefore, in the context of the regulation of hematopoiesis, they may contribute to the HSC niche with mechanisms that, at least in part, may overlap or complement those employed by the osteoclasts.
Winkler et al. 39 showed that administration of granulocyte colony stimulating factor (G-CSF) depleted the endosteal surface of both endosteal osteoblasts and endosteal macrophages, denominated osteomacs, which was concomitant with the HSC mobilization. Osteomacs could be pivotal in HSC egress because their depletion in Fas-induced apoptosis transgenic mice or by administration of chlodronate-loaded liposomes reduced trophic cytokines at the endosteum and HSC mobilization upon G-CSF administration. The effect of G-CSF appeared to be mediated by the restriction of G-CSF receptor to the monocytic lineage, which was depleted in the bone marrow when the cytokine was administered. 40 It is likely that one of the mechanisms underlying the role of monocytic cells in the HSC niche is the production of yet-to-be identified factors that support osteoblasts in vivo , although a direct evidence that this is related to the HSC niche is still lacking. In conditional depletion models of bone marrow mononuclear phagocytes, the expression of CXCL12 was found to be diminished, contributing to HSC egress. Consistently, in this model, the response to CXCR4 antagonists and to G-CFS was enhanced. 41 Figure 3 Genetic studies. Cartoon illustrating the effect of deletion in mice of the Id1 and the CREBB genes on bone mass and myelopoiesis.
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Role of Erythropoietin
In 1971, Perris et al. 42 had reported an association of the bone marrow response with acute bleeding due to hypocalcemia and release of PTH, observing a delay of hematocrit recovery in thyroparathyroidectomized rats compared with controls, and a restoration upon PTH infusion ( Table 2 ). These observations suggest a close relationship between erythropoiesis and bone resorption.
Erythropoietin is the major physiological cytokine that supports erythropoiesis. Factors released by erythroid cells in response to this hormone regulate the osteoblast / osteoclast coupling. Erythropoietin stimulates osteoclastogenesis in the first instance, followed by an increase in osteoblastogenesis that is induced either by erythropoietin directly or through the expression of bone morphogenetic proteins 2 and 6 by HSCs through the Jak / Stat signaling. 43 Oncostatin M, a member of the gp130 family of cytokines, is also induced strongly in erythroblasts in response to erythropoietin. 44 Oncostatin M binds to and signals the osteoblasts to produce RANKL, subsequently inducing osteoclast differentiation 45 ( Table 2 ). Therefore, oncostatin M contributes to the orchestrated response of erythroid cells to erythropoietin and to the changes in the local bone structures and osteoclast response. Consistent with this knowledge, mice treated with a clinically relevant dose of erythropoietin showed a rapid loss of the trabecular bone volume. Interestingly, bisphosphonates blocked the erythropoietin-induced bone loss and the magnitude of the erythroid response to erythropoietin, 46 once again suggesting a close association between bone resorption and myelopoiesis. In fact, the article points to the interplay between erythroid development and skeletal homeostasis, suggesting that bone remodeling is required for attaining sufficient bone marrow space for erythroid expansion. This has been proposed by Suda 47 to reflect the phylogenic process of bone marrow formation within the bone cavity.
Anti-resorptive Drugs
Recent papers have directly addressed the importance of osteoclast activity in the context of the regulation of hematopoiesis, with, however, contradictory results ( Table 2 ). Lymperi et al. 48 showed that inhibition of osteoclast function reduces HSC numbers in vivo . To address this question, they tested the effects of bisphosphonates on hematopoiesis, and observed that mice treated with bisphosphonates displayed a drop in HSCs in the bone marrow. They also observed impairment of the engraftment of bone marrow cells harvested from treated animals. Bisphosphonates also abolished the HSC increment produced by PTH, confirming that this hormone acts on hematopoiesis, at least in part, through the enhancement of osteoclast activity. They also observed that a larger fraction of LSK cells in the bone marrow of treated mice entered the cell cycle, suggesting that osteoclast impairment promotes proliferation and subsequent differentiation of progenitor cells, a finding in line with the observations in the Id1 − / − and the Crebbp − / − mice. 32, 33 HSC impairment was considered a consequence of niche manipulation, because the bone marrow from untreated donor mice transplanted into mice previously treated with bisphosphonates showed a delay in hematopoietic recovery compared with untreated controls. Therefore, the authors concluded that osteoclast function is fundamental for the maintenance of a correct HSC niche. 48 In a previous work, however, Takamatsu et al. 49 had found that short-term G-CSF administration increased bone resorption concomitant to the egress of HSC. In this circumstance, the bisphosphonate pamidronate reduced the G-CSF-induced bone resorption but, instead of decreasing, it increased the number of HSCs mobilized from bone marrow, suggesting that bone resorption is not the direct cause of HSC mobilization but rather a parallel event.
Miyamoto et al. 50 performed an elegant study using various models of osteoclast-deficient mice and also concluded that osteoclasts are dispensable for HSC maintenance and mobilization. They caused HSC mobilization in mice by sequential treatments with G-CSF and counted the number of LSK cells in the peripheral blood. They observed that mobilization of HSCs from bone marrow was increased in bisphosphonate-or RANKL antibody-treated mice compared with controls. Likewise, the number of HSCs mobilized into the blood was higher in mice with osteopetrotic genotypes, including the macro phage colony stimulating factor-, RANKL-and c-Fos-deficient mice. Consistently, mice deficient in the anti-osteoclastogenic cytokine osteoprotegerin, whose phenotype is characterized by increased numbers of osteoclasts and exacerbated bone resorption, exhibited reduced HSC mobilization, leading the authors to conclude that osteoclasts prevent HSC mobilization and may be negative regulators of the hematopoietic system. 50 It is worth noting, however, that, according to the involvement of monocytic phagocytes in the regulation of the HSC niche, 39 -41 drugs disrupting osteoclasts could also trigger a positive feedback loop that could affect the homeostasis of bone marrow macrophages through their myeloid progenitors.
A recent report suggested that bone marrow B lymphopoiesis is also regulated by osteoclast activity. Osteopetrosis was induced in normal mice by injections of zoledronic acid, which caused B-cell number to decrease specifically in the bone marrow. This effect was due to a decrease in the expression of CXCL12 and IL-7 by stromal cells, which led to retention of B-cell progenitors outside of the bone marrow niches. Similar results were observed in the osteopetrotic oc / oc mice, suggesting that they were not due to the zoledric acid itself but to the microenvironmental condition created by reduced osteoclast activity. 51 Lastly, a very recent paper suggested that osteoclasts promote the formation of the HSC niche by controlling the maturation of osteoblasts. 52 In oc / oc mice and in wild-type mice treated with zoledric acid, the frequency of LSK cells in the bone marrow decreased by > 90 % , whereas that of mesenchymal progenitors increased to 80 % of the total number of bone marrow cells compared with 20 % in wild-type untreated mice. These mesenchymal progenitors were not capable of recruiting LSK cells and their differentiation into the osteoblast lineage was impaired, suggesting that osteoclasts could affect HSC niche development through their influence on osteoblast differentiation.
Clinical Considerations
From this set of data, it is clear though that the field is rapidly expanding, but that a consensus on the role of osteoclasts and bone resorption in the regulation of hematopoiesis is not yet possible because of the heterogeneity of observations and experimental data. However, some considerations can be drawn, especially in the clinical context because treatments
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A Teti with current bone-seeking drugs may have implications on the well-being of patients with hematological failures. For instance, bisphopshonates have been shown to suppress HSC in the bone marrow 48, 52 and to increase its mobilization into the peripheral blood. 48, 50 This may implicate that caution must be used for the engraftment of bone marrow when anti-resorptive drugs are used, but could also implicate that treatment with anti-resorptive drugs could improve the yield of HSCs from the peripheral blood of donors in which HSC mobilization is enhanced by treatment with G-CSF for transplantation purpose. Likewise, it is established since the pioneer paper by Calvi et al. 53 that PTH increments HSC number in the bone marrow and enhances the engraftment of transplanted HSCs, a finding that has been confirmed more recently by various studies. 2 Therefore, administration of PTH can be envisioned as a potential treatment of both donors and hosts to improve the HSC yield in the former and their engraftment in the latter. These implications could be highly relevant also in case of autologous transplant in patients affected by multiple myeloma, a disease that presents with serious bone involvement often treated with anti-resorptive therapy.
In osteopetrotic patients subjected to bone marrow transplantation, a frequent adverse effect due to the appearance of functional osteoclasts is the development of hypercalcemia, for which patients are treated with anti-resorptive drugs. 54 It is already known that caution must be used for the treatment of infants with these drugs as they can greatly affect bone turnover with consequences on bone quality. The studies available so far indeed suggest that even more caution is needed as inhibition of bone resorption may also worsen the engraftment and maintenance of HSC, thus compromising the beneficial effects of bone marrow transplantation. Similarly, children with osteogenesis imperfecta or other diseases characterized by severe bone loss are often treated with bisphosphonates. 55 Concerns have been raised on the long-term use of bisphosphonates in childhood because, by blocking the bone turnover, they are known to cause a paradoxical bone fragility later in life. 56 There is now an additional concern as these kids should probably be monitored also for hematological failures in the light of the putative negative role of osteoclast inactivity on HSC maintenance in bone marrow.
Finally, the regulatory nexus between erythropoietin administration and bone remodeling may also have important clinical implications, for example, in explaining the skeletal deformities in -thalassemia, which is characterized by increased erythropoietin production. Likewise, patients affected by renal failure are treated with erythropoietin, which may have an impact on their severe osteodystrophy. Moreover, excess of erythropoietin administration in preparation of autologous blood transfusion may have implications, for instance, in patients affected by leukemia or multiple myeloma, considering the serious bone complications observed in these onco-hematological diseases. 47 
Conclusions
In conclusion, this rapidly expanding field of research is likely to shortly address new questions on the role of osteoclasts in the regulation of hematopoiesis and on the underlying molecular mechanisms. It is necessary though to monitor the new findings, trying to unequivocally clarify whether active osteoclasts are an advantage or a disadvantage for HSC maintenance, mobilization and progression towards myelopoiesis, especially in the clinical context.
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